CMB International Leads $100M Series B Round Into US Biopharmaceutical Firm

Login to View

U.S. biopharmaceutical company Apollomics, Inc., has raised US$100 million in a series B financing round, led by CMB International (CMBI), a subsidiary of China Merchants Bank. The round was also participated in by existing series A round investor, OrbiMed Asia, according to an announcement today. 

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in

China Money Network Subscription